Subsequent validation studies and meta-analyses have consistently confirmed CCL-14’s clinical utility across diverse patient populations, establishing it as one of the most feasible biomarker for persistent AKI prediction [57,58]. This evidence concerns the gene CCL14 and acute kidney injury.